Search -

Displaying 41 - 60 of 96

Sort: Relevancy | Date

News Daily News

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

Shelley Wood

May 30, 2023

News Opinion CV Team Dispatch

May 2023 News Roundup

L.A. McKeown

May 01, 2023

News Daily News

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

L.A. McKeown

April 19, 2023

News Daily News

AHA/ACC Scientific Statement Supports Exercise Therapy in HFpEF

L.A. McKeown

March 27, 2023

News Daily News

Vast Majority of HFrEF Patients Eligible for Vericiguat

L.A. McKeown

February 08, 2023

News Daily News

Concerning or Reassuring? Long After COVID-19, CMR Still Yields Clues

Michael O'Riordan

October 03, 2022

News Daily News

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

Michael O'Riordan

September 09, 2022

News Daily News

Older Adults See Rebound in Rates of HF-Related Death: CDC Data

Caitlin E. Cox

September 09, 2022

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

Shelley Wood

August 22, 2022

News Daily News

AHA Urges More Home-Based Dialysis in Advanced Kidney Failure

Michael O'Riordan

August 18, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2022

Todd Neale

August 01, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for June 2022

Caitlin E. Cox

July 04, 2022

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

Shelley Wood

May 23, 2022

News Conference News HRS 2022

Gains in HF Drug Therapy Raise Questions About ICD Benefit in Modern Era

Todd Neale

May 02, 2022

News Daily News

CVD Hospitalizations Spiked in Aftermath of 2020 US Election

Michael O'Riordan

April 22, 2022

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Shelley Wood

April 01, 2022

News Daily News

Guideline-Directed Therapies Underused in Frail HF Patients

L.A. McKeown

March 11, 2022

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

L.A. McKeown

December 07, 2021

News Opinion CV Team Dispatch

December 2021 News Roundup

L.A. McKeown

December 01, 2021

News Features

When the Time Comes to Stop Oral Anticoagulation: Options and Obstacles

Todd Neale

September 28, 2021

Advertisement

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

May 2023 News Roundup

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

AHA/ACC Scientific Statement Supports Exercise Therapy in HFpEF

Vast Majority of HFrEF Patients Eligible for Vericiguat

Concerning or Reassuring? Long After COVID-19, CMR Still Yields Clues

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

Older Adults See Rebound in Rates of HF-Related Death: CDC Data

What’s Going to Be Hot at ESC 2022?

AHA Urges More Home-Based Dialysis in Advanced Kidney Failure

TCTMD’s Top 10 Most Popular Stories for July 2022

TCTMD’s Top 10 Most Popular Stories for June 2022

Dapagliflozin Boosts Health Status Across LVEF Range

Gains in HF Drug Therapy Raise Questions About ICD Benefit in Modern Era

CVD Hospitalizations Spiked in Aftermath of 2020 US Election

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Guideline-Directed Therapies Underused in Frail HF Patients

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

December 2021 News Roundup

When the Time Comes to Stop Oral Anticoagulation: Options and Obstacles

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content